[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355566-105":59,"doc-detail-355566-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-systematic-review-of-the-economic-burden-of-prostate-cancer-direct-and-indirect-cost-perspectives","A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives","","A Systematic Review of the Economic Burden of Prostate Cancer evaluates recent cost-of-illness evidence on direct and indirect expenditures under current clinical guidelines. It uses PICOS to search PubMed, the Cochrane Library, and EconLit, extracting total, direct, and indirect costs from studies published between January 2015 and October 2025. Costs are converted to 2025 USD and study quality assessed with a simplified CHEERS checklist. Ninety-five studies are included, showing wide variation in direct medical costs and productivity losses as key drivers of indirect costs.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-systematic-review-of-the-economic-burden-of-prostate-cancer-direct-and-indirect-cost-perspectives/355566/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-systematic-review-of-the-economic-burden-of-prostate-cancer-direct-and-indirect-cost-perspectives/355566.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the review address about prostate cancer costs?","Question",{"text":113,"@type":114},"It reviews recent cost-of-illness studies focused on both direct and indirect costs associated with prostate cancer, emphasizing evidence aligned with current clinical guidance.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were studies identified and how were costs standardized?",{"text":118,"@type":114},"The review uses PICOS and searches PubMed, the Cochrane Library (with MeSH and free-text), and EconLit (free-text only). Extracted costs are converted to 2025 USD.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the main findings about direct and indirect costs?",{"text":122,"@type":114},"Direct medical costs vary substantially by stage, treatment, and country, escalating with progression to metastatic disease. Indirect costs range broadly and can account for up to 30% of total costs, driven mainly by productivity losses from premature mortality.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355566,1790324979,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","PharmacoEconomics (2026) 44:559–583  \n[https://doi.org/10.1007/s40273-026-01594-4](https://doi.org/10.1007/s40273-026-01594-4)  \nA Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives  \nJosep Darbà1 · Meritxell Ascanio2 · Antonio Rodríguez2  \nReceived: 15 July 2025 / Accepted: 20 January 2026 / Published online: 6 February 2026 © The Author(s) 2026  \nAbstract  \nIntroduction Prostate cancer (PC) is the second most common cancer in men. Although many studies have assessed its economic burden, no recent reviews have focused on studies conducted under current clinical guidelines. This study systematically reviews recent cost-of-illness studies evaluating direct and indirect costs associated with PC.  \nMethods A systematic search was conducted using the PICOS framework and a combination of free-text and MeSH terms in PubMed and the Cochrane Library, and only free-text terms in EconLit. The search included articles published between January 2015 and October 2025. Data on total, direct, and indirect costs were extracted and synthesized. All costs were converted to 2025 USD, and quality of studies was assessed with a simplified version of the CHEERS checklist.  \nResults Ninety-five studies met the inclusion criteria. Direct medical costs for non-metastatic prostate cancer (nmPC) varied widely by disease stage, treatment, and country, ranging from approximately US$1200 to US$280,000 per patient-year, with higher costs observed in advanced stages and in patients experiencing treatment-related adverse events (AEs) . Progression to metastatic disease was associated with a marked cost escalation, with annual costs largely driven by systemic therapies and skeletal-related events. Indirect costs ranged from US$666 to US$12,900 per patient-year and accounted for up to 30% of total PC-related costs, primarily due to productivity losses from premature mortality.  \nConclusions PC imposes a substantial economic burden on healthcare systems and society, particularly in advanced stages. Policy promoting early detection, risk-adapted treatment, and equitable therapy access may help contain costs. Further research should address the economic impact of emerging diagnostics and minimally invasive interventions.  \n* Josep Darbà [darba@ub.edu](darba@ub.edu)  \nMeritxell Ascanio  \n[meritxell.ascanio@bcnhealth.com](meritxell.ascanio@bcnhealth.com)  \nAntonio Rodríguez  \n[antonio.rodriguez@bcnhealth.com](antonio.rodriguez@bcnhealth.com)  \n1 Department of Economics, Universitat de Barcelona, Diagonal 696, 08034 Barcelona, Spain  \n2 BCN Health Economics and Outcomes Research S.L., Travessera de Gràcia, 62, 08006 Barcelona, Spain  \n1 Introduction  \nProstate cancer (PC) is the fourth most common cancer worldwide and the second most common in men, with an estimated 1,467,854 new cases and 397,439 deaths recorded in 2022 [1] . It is projected that approximately one in eight men will be diagnosed with PC during their lifetime [2] . Major risk factors include age, family history, and genetic predisposition, while lifestyle factors such as smoking, diet, lack of physical activity, medication use, and occupational exposures may also contribute to increased incidence [3] . The highest PC incidence rates are reported in North and South America, Europe, Australia, and the Caribbean, with particularly high rates observed among Black and African American populations. In recent years, incidence and mortality rates have either stabilized or declined across most regions [4] . However, trends in incidence remain closely  \nlinked to the adoption of prostate-specific antigen (PSA) screening, especially in high-income countries [5, 6] .  \nPC displays highly heterogeneous biological behaviour, ranging from indolent tumours that never metastasize to highly aggressive forms, posing significant challenges for screening, diagnosis, and treatment [7] . To assess how aggressive PC is, several tests and procedures are performed to determine it","cbCaitzcxbOjuiJd","https://ap.wps.com/l/cbCaitzcxbOjuiJd","pdf",911964,25,"English","# Abstract\n# Introduction\n## Clinical burden and epidemiology\n## Heterogeneity, staging, and guidelines\n## Precision medicine advances and treatment complexity\n## Need for updated economic assessment\n# Methods\n## PICOS-based literature search and data extraction\n## Cost conversion and quality assessment\n# Results\n## Direct medical costs by disease stage and country\n## Indirect costs and productivity losses\n# Conclusions","[{\"question\":\"What question does the review address about prostate cancer costs?\",\"answer\":\"It reviews recent cost-of-illness studies focused on both direct and indirect costs associated with prostate cancer, emphasizing evidence aligned with current clinical guidance.\"},{\"question\":\"How were studies identified and how were costs standardized?\",\"answer\":\"The review uses PICOS and searches PubMed, the Cochrane Library (with MeSH and free-text), and EconLit (free-text only). Extracted costs are converted to 2025 USD.\"},{\"question\":\"What are the main findings about direct and indirect costs?\",\"answer\":\"Direct medical costs vary substantially by stage, treatment, and country, escalating with progression to metastatic disease. Indirect costs range broadly and can account for up to 30% of total costs, driven mainly by productivity losses from premature mortality.\"}]","A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives | PDF",1790119902,63,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbbe1561424a79fc79fe05ddff6be653.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f35e9cbf364905fa2a0a5b89050512e7.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96c284cc41855c0fd9e8df6ad1a06854.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cad5b580864548c27b91e61c55ff74f.webp",980,1301]